Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Xeris Biopharma Holdings
ISIN US98422E1038
|WKN A3C4ZC
Market cap (in EUR)
1,360 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,360 m |
| EPS, EUR | -0.09 |
| P/B ratio | 97.6 |
| P/E ratio | 123.8 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 259 m |
| Net income, EUR | 0 m |
| Profit margin | 0.19% |
What ETF is Xeris Biopharma Holdings in?
There are 32 ETFs which contain Xeris Biopharma Holdings. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xeris Biopharma Holdings is the L&G Pharma Breakthrough UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.